MOTS-c Where to Buy: What the Lot Number Must Match

MOTS-c where to buy resolves to exactly one kind of seller: a research-chemical supplier. No pharmacy dispenses it, no clinic can prescribe it, and no regulator has assessed a single batch of it, so nothing external separates one vial from another.

What does separate them is the analytical record a supplier is prepared to publish. This guide sets out the criteria that can be failed on documents you can read, marks which of them you can check before paying and which only resolve at delivery, and then applies the same list to the vendor advertised on this page.

MOTS-c where to buy: the criteria that can actually be failed

A criterion phrased as a quality cannot be failed. Reputable, trusted, and premium are not observations, so they rank nothing and exclude nobody. A criterion phrased as a document can be failed, because either the document exists and says something specific or it does not.

The final column matters more than it looks. Six of the seven criteria below can be settled before your card is charged. Only one of them, the match between certificate and vial, stays open until the parcel is in your hands, which means it is the only criterion a supplier can pass on the website and fail in the box.

Two details inside those rows carry most of the weight. Peptide purity is read at 214 nm, where the amide backbone absorbs, so a certificate that omits the wavelength has dropped the one parameter that makes its number comparable. And a seller that labels material for laboratory research while printing an injection schedule beside it has contradicted its own paperwork in public.

What a certificate of analysis covers, and what it silently excludes

A certificate records what one laboratory measured, on one sample, drawn from one lot, on one date. That is the entire scope of the document. It is not an approval, not a licence, and not a statement about anything the analyst did not run.

Three limits follow directly. It says nothing about how the material was made, because analysis happens downstream of synthesis. It does not establish that the sample represents the lot unless the sampling is described, which it almost never is. And it cannot be transferred to a different lot, which is why one certificate covering a product line rather than a batch is a brochure with a table in it.

There is a further gap specific to unapproved compounds. No pharmacopoeial monograph exists for MOTS-c, so there is no published specification against which a certificate could be judged compliant or non-compliant. The validation principles in ICH Q2(R2) describe what an analytical method has to demonstrate to be fit for purpose, but no research supplier is obliged to follow them, and most do not state whether their contract laboratory did.

Identity: the theoretical mass of MRWQEMGYIFYPRKLR

Purity and identity answer different questions, and most certificates answer only the easier one. A sample can be 99 percent pure and 100 percent not MOTS-c. Identity comes from mass spectrometry: the measured mass of the molecule is set against the theoretical mass calculated from the sequence.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA region, sequence MRWQEMGYIFYPRKLR. That sequence gives an average mass of about 2,174.6 Da and a monoisotopic mass of about 2,173.1 Da. Those are two different targets, roughly 1.5 Da apart, and a certificate that prints a single theoretical figure without saying which convention it used has withheld a parameter you need in order to judge agreement.

On an electrospray instrument the deconvoluted measured mass should land within a few daltons of the correct theoretical value. A gap of tens of daltons is not instrument noise. It points to a deletion sequence, an oxidised methionine, a different modification, or a different peptide altogether, and MOTS-c contains two methionines, so a mass shift of roughly 16 Da has an obvious candidate explanation that the raw spectrum would show and a summary line would not.

Read the number, not the verdict. Certificates routinely print identity confirmed with no measured mass beside it, which asks you to accept a conclusion while withholding the observation it rests on. There is no technical reason to omit it.

Label mass is not peptide mass: water and counterion

A vial labelled 10 mg contains 10 mg of powder. Powder is not the same thing as peptide. Residual water, measured by Karl Fischer titration, takes some of that mass. The counterion takes more, and for MOTS-c the effect is larger than it is for many peptides.

Peptides purified by reversed-phase HPLC are commonly isolated as trifluoroacetate salts, because trifluoroacetic acid is a standard mobile-phase additive. TFA associates with basic sites, and MOTS-c has several: three arginines, one lysine, and a free N-terminal amine. The table below works through what each additional TFA equivalent does to the peptide content of a 10 mg vial and to the real cost per milligram at the discounted price of $37.50.

These are calculated figures from the sequence and the mass of trifluoroacetic acid, not measurements of any particular batch. The point is the size of the range: between a label taken at face value and a heavily loaded TFA salt sits a 21 percent difference in delivered peptide, which no chromatogram will reveal, because a salt is not covalently bound and mass spectrometry reports the free peptide either way. Only a stated salt form, or an ion-chromatography or fluorine assay, closes that gap.

Residual trifluoroacetate is also not inert. It has been shown to inhibit proliferation in osteoblast and chondrocyte culture at low concentrations, which is a live concern for anyone using the material in cell work rather than a purely commercial footnote. The same arithmetic sensitivity turns up again at reconstitution, which we work through in the peptide calculator and dose accuracy guide, and the full cost breakdown sits in our MOTS-c price analysis.

Scoring the supplier on this page

Ascension Peptides is the supplier this site links to, and the disclosure on the card above is accurate: these are affiliate links. That is a reason to state the case as checkable claims rather than to hide it behind an endorsement.

On the first two criteria the position is stronger than the category norm. The vendor publishes certificates from two independent laboratories rather than one, Kovera Labs on batch #24-05260628 and MZ Biolabs on batch #24-01260229, and the lot numbers are printed rather than implied. Two laboratories examining the same material is a cross-check; one laboratory agreeing with itself is a single observation. We have not commissioned or repeated that testing, and those are the vendor's own published records.

The commercial facts are simple because there is only one presentation. MOTS-C is sold as a single 10 mg vial at $75.00, which the code PEPTIDEDECK reduces to $37.50, or $3.75 per milligram before the counterion correction above. Buying three, five, or ten vials takes 3, 5, or 10 percent off the list price instead. Free shipping starts at $250, so one discounted vial does not reach it and roughly seven do. Anyone working out mots-c peptide where to buy on cost alone should be comparing corrected per-milligram figures across suppliers, not headline vial prices.

Criteria three through six are not ours to pass on the vendor's behalf. They are settled by opening the certificates and reading the chromatogram, the measured mass, the water figure, and the endotoxin result. A page that tells you a PDF exists has told you the least useful thing about it.

What the documents cannot tell you about the compound

Passing every criterion above establishes what is in the vial, to the limit of what paperwork can establish. It says nothing about whether the compound does anything, and that is a separate question with a much thinner file behind it.

MOTS-c was characterised by Lee and colleagues in Cell Metabolism in 2015 as a mitochondrial-derived peptide acting on metabolic homeostasis through AMPK, in cell culture and in mice. That work, and the rodent and cell literature built on it, is the substance of the evidence base. The only human clinical programme belonged to CB4211, a MOTS-c analogue rather than MOTS-c itself, which completed a Phase 1a/1b study of 88 participants (NCT03998514) in April 2021 before its sponsor wound the company down. There is no Phase 3, and no large human efficacy trial of MOTS-c exists to be waiting on.

That is also the honest answer to why no pharmacy route exists. MOTS-c is not an approved drug anywhere, and it is not on the FDA's 503A bulk drug substances list, so a compounding pharmacy has nothing to compound with lawfully. MOTS-c-related bulk substances are scheduled for discussion at the Pharmacy Compounding Advisory Committee meeting on 23 July 2026, a process that has not concluded and that does not change the position today. For the wider category framing see what research peptides actually are, and for a compound at the opposite end of the evidence scale, the same verification exercise applied to a Phase 3 asset sits in our retatrutide sourcing guide.